Eisai To Use Three-Tiered Pricing In India For Breast-Cancer Drug
This article was originally published in PharmAsia News
Executive Summary
Eisai plans to extend its affordable-pricing system for certain drugs in India and other emerging markets to its third drug in India, Halaven (eribulin) breast-cancer drug to be priced at three levels according to income.